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Abstract 
A number of different serum biomarkers are currently 
being evaluated for their potential use as diagnostic and 
prognostic biomarkers in Glioblastoma Multiforme. 
Amongst these, a vast number of different microRNAs 
have been studied, that are up-regulated or down-
regulated in relation to Glioblastoma Multiforme. 
Different studies have found numerous associations of 
these different microRNAs with recurrence, Karnofsky 
Performance Score, Progression Free Survival and Overall 
Survival. Other than microRNAs, serum Glial Fibrillary Acid 
Protein, cytokines and YLK-40, as well as a number of 
other candidate serum biomarkers are being 
studied.More studies, with larger sample sizes are 
required before these serum biomarkers can be routinely, 
and reliably used in clinical practice. Use of serum 
biomarkers can provide a non-invasive means for 
diagnosing and monitoring disease. 
Keywords: Glioblastoma multiforme, Serum biomarkers, 
microrna, GFAP, YLK-40. 
Introduction 
The diagnosis of brain tumours including Glioblastoma 
Multiforme (GBM), their progression, as well as recurrence 
are presently monitored through imaging modalities. The 
gold standard for diagnosis is histopathology, which is 
performed on a tissue sample acquired through invasive 
neurosurgery. A non-invasive method to diagnose and 
monitor disease progression can be the use of serum 
biomarkers, on the same lines as most systemic infections 
and even some malignancies (Prostate Specific Antigen 
for prostate). A multitude of molecules are currently being 
evaluated for potential use as serum biomarkers for 
diagnosis and disease progression of GBM, and even 
though some of these biomarkers have shown reasonable 
sensitivity and specificity, none of these are used 
routinely in clinical practice as yet. We present a review of 
the ongoing research on potential serum biomarkers for 
their use in screening and prognosis of GBM. 
Review of Evidence 
MicroRNAs are small non coding RNA molecules. Several 
studies have looked at an array of different microRNAs 
(miRNA) and their potential use as biomarkers of GBM.1-4 
Lan et al.1 reported, serum exosomal miR-301a to be 
significantly up-regulated in high grade gliomas. The 
authors also observed association of miR-301a with lower 
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Figure (a & b): MRI axial sections T1WI plain and with contrast, showing typical 
features of a left temporal lobe glioblastoma multiforme.
Karnofsky Performance Score (KPS). Resection of the 
tumour resulted in decreased levels of miR-301a, whereas 
tumour recurrence resulted in increased levels.1 Yue and 
colleagues, analyzed the expression of a different 
microRNA, miR205  and found serum levels of miR205 to 
be significantly lower in patients with GBM when 
compared with controls.2 After tumour resection miR205 
was increased, and it decreased with recurrence. Another 
significant correlation observed in this study was of low 
miR205 with increasing pathological grade, and lower KPS 
score. Longer Overall Survival (OS) was seen in patients 
with elevated serum miR205 compared to patients with 
lower levels of serum miR205.2 MGMT methylation status 
has been linked with prognosis in GBM.3 Wang et al.,4 
observed a correlation of elevated serum levels of miR-
451a with positive MGMT expression. They also observed 
that low serum level of another microRNA, miR-485-3p, 
was associated with poor PFS and OS.4 In a recent meta-
analysis of 16 studies regarding different circulating 
miRNAs (from either serum or plasma) in glioma, it was 
suggested that circulating miRNAs can potentially be used 
as a means of early diagnosis. All the studies in this meta-
analysis used qRT-PCR for detecting circulating miRNAs. 
Different miRNAs were observed to be either up-regulated 
or down-regulated in relation to GBM diagnosis, 
recurrence, and OS in all the studies included.5 
Some other biomarkers that have been analyzed other 
than microRNAs include  Glial Fibrillary Acid Protein 
(GFAP), YKL-40, cytokines and other serum proteins. 
Serum GFAP has been considered as a potential 
diagnostic biomarker for GBM, however it could not be 
established as a reliable indicator of tumour recurrence.6-
8 Nijaguna et al., in a study of 194 patients identified an 
18 serum cytokine signature for GBM. Fifteen of these 
were increased and 3 were decreased in the serum of 
GBM patients. These cytokines were also analyzed from 
tumour samples and 13 of these showed similar 
regulation at transcript level in the GBM tissue.9 Elstner et 
al., analyzed serum proteins and identified BMP2 (cell 
proliferation), CXCL10 (cell motility) and HSP70 (anti-
apoptotic) as potential serum biomarkers for GBM 
diagnosis.10 YKL 40 is an extracellular matrix glycoprotein 
that has also been studied as a serum biomarker of GBM. 
In several studies it has also shown potential as a 
prognostic biomarker.11,12 
Conclusion 
Several different serum biomarkers have shown 
promising results for diagnosing, predicting severity and 
recurrence as well as OS in GBM. However, before these 
biomarkers can be routinely used in clinical practice, 
studies with larger sample sizes, done in different 
populations of GBM patients would be required. As there 
is a multitude of serum biomarkers that all show some 
association with GBM prognosis, combining them in a 
panel or algorithm through more extensive translational 
research for clinical use would be pragmatic.  
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